XNAS · Diagnostics & Research
Last stored close · Nov 10, 2026
Close · Nov 10, 2026
$214.91-2.66%
Model Target
available with Pro
Implied upside
vs the model target
Valuation methods
the methods behind the target
TickerWhale Score
58/100
Positive
Score components
TickerWhale View
Illumina scores 58 out of 100 overall, which we rate positive. Quality & growth is its strongest area and Valuation its weakest.
What helps
- Quality & growth
- Sentiment Signal
What to watch
- Technical
- Valuation
- Risk
Quality & growth
30%78Strong
- Revenue growth 4.9%
- EPS growth -32.1%
Valuation
25%47Moderate
- P/E 39.9
- EV/Sales 7.5
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
#330 by market cap in our coverage · ~8,650 employees · Listed 2000-07-28 · www.illumina.com
Price history
Intraday to five-year windows are free with an account
Members switch between 1D, 1M, 6M, 1Y, 2Y and 5Y and see the live price. Signed out, this is the one-year stored series the technicals below are computed from.
Market intelligence
Peer position
#58 / 139sector rank by TickerWhale Score
TickerWhale Score 58 vs sector average 54.6 (+3.4)
Revenue growth (industry)Top 79%
Gross margin (industry)Top 6%
Return on equity (industry)Top 18%
P/E (industry)Pricier than 64%
Technical analysis
our read · what classic indicators sayTickerWhale technical read
49/100Moderate vs universe
Ranks 49th of 100 covered names on our technical composite — the composite itself scores 56/100 · 25% of the TickerWhale Score
Classic chart indicators
Sell
2 buy · 5 sell · 1 neutral of 8 votes
TickerWhale rates ILMN's technical setup middling — 49th percentile of the covered universe. Classic chart indicators lean sell — they read this stock on its own over days, where our score ranks it against every covered name over months, so the two often part company.
Moving averages
2 / 9constructive
- vs 200-day+20.3%
- vs 50-day-13.8%
Momentum
Mixed
- RSI (14)37 · neutral
- Stochasticbuy
- CCIsell
- Williams %Rbuy
Trend
Weak
- ADX (14) trend strength29· trending
- MACD (12,26,9)sell(histogram -6.995)
How the classic verdict is reached
Moving averages (9) agree on sell — 2 buy vs 7 sell — and carry one vote between them.
Oscillators (7) vote individually: 2 buy · 4 sell · 1 neutral.
Result — 2 buy vs 5 sell of 8 votes = Sell. Neutral votes never decide the verdict.
Fundamentals & valuation
2026-11-10 · revised_latestValuation multiples
- P/E (TTM)39.9
- P/S (TTM)7.3
- P/B11.6
- EV/EBITDA—
- EV/Sales7.5
- PEG—
Profitability & returns
- Gross margin66.4%
- Net margin18.4%
- ROE29.9%
- Debt/Equity0.70
Growth
- Revenue growth (YoY)4.9%
- EPS growth (YoY)-32.1%
Green favourable · red stretched — multiples and D/E vs industry peers, margins and growth vs absolute thresholds.
Market capitalisation — $32.9B
Fundamentals history
Reported statement totals across recent periods.
Fundamentals are stored revised/latest (ADR-009): each period reflects the most recent vendor refresh, NOT point-in-time as-reported values. Do not use this series to claim what was known on a past date.
Model Target
Model Target is a Pro feature
Scores, factors and technicals stay free. The model's price target is part of TickerWhale Pro.
The Model Target is a TickerWhale Pro feature
A target exists for this name — the model priced it in the latest nightly run. Pro members see the target, its range and the methods behind it; one name's target is free every trading day.
Or see the current free one: KNSA →
Peers
| Company | Score | Pulse | P/E | P/E fwd | P/B | EV/Sales | Price | Chg | Estimate | Upside | Rev. gr. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ILMNCurrentIllumina | 58 | 56 | 39.9 | — | 11.6 | 7.5 | $214.91 | -2.66% | +4.9% | ||
| EXELExelixis | 82 | 88 | 21.3 | — | 9.9 | 7.4 | $70.58 | -1.62% | +9.2% | ||
| KNSAKiniksa Pharmaceuticals International plc. - | 79 | 81 | 98.2 | — | 12.1 | 9.3 | $95.02 | -3.79% | +58.9% | ||
| THCTenet Healthcare | 79 | 81 | 10.9 | — | 5.2 | 1.6 | $290.27 | +0.44% | +7.5% | ||
| INCYIncyte | 76 | 67 | 15.5 | — | 3.9 | 3.6 | $120.30 | -1.30% | +26.9% | ||
| LIVNLivaNova | 76 | 84 | 27.2 | — | 3.9 | 3.3 | $91.14 | -1.59% | +12.4% |
News, sentiment, the Street view and Ask Willy are free with an account
A free account shows the stories attached to this name, the Sentiment Signal breakdown, analyst consensus, the options read and the AI narration of the model output.